RT Journal Article
SR Electronic
T1 COVID-19 vaccine effectiveness during a prison outbreak when the Omicron was the dominant circulating variant— Zambia, December 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.06.22274701
DO 10.1101/2022.05.06.22274701
A1 Simwanza, John
A1 Hines, Jonas Z.
A1 Sinyange, Danny
A1 Sinyange, Nyambe
A1 Mulenga, Chilufya
A1 Hanyinza, Sarah
A1 Sakubita, Patrick
A1 Langa, Nelia
A1 Nowa, Haggai
A1 Gardner, Priscilla
A1 Saasa, Ngonda
A1 Chipeta, Gabriel
A1 Simpungwe, James
A1 Malambo, Warren
A1 Hamainza, Busiku
A1 Kapata, Nathan
A1 Kapina, Muzala
A1 Musonda, Kunda
A1 Liwewe, Mazyanga
A1 Mwale, Consity
A1 Fwoloshi, Sombo
A1 Mulenga, Lloyd B.
A1 Agolory, Simon
A1 Mukonka, Victor
A1 Chilengi, Roma
YR 2022
UL http://medrxiv.org/content/early/2022/06/08/2022.05.06.22274701.abstract
AB During a COVID-19 outbreak in a prison in Zambia from 14th to 19th December 2021, a case control study was done to measure vaccine effectiveness (VE) against infection and symptomatic infection, when the Omicron variant was the dominant circulating variant. Among 382 participants, 74.1% were fully vaccinated and the median time since full vaccination was 54 days. There were no hospitalizations or deaths. COVID-19 VE against any SARS-CoV-2 infection was 64.8% and VE against symptomatic SARS-CoV-2 infection was 72.9%. COVID-19 vaccination helped protect incarcerated persons against SARS-CoV-2 infection during an outbreak while Omicron was the dominant variant in Zambia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Excellence in Research Ethics Science converge Zambia gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript